XML 48 R23.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Collaboration and License Agreements (Tables)
6 Months Ended
Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Summary of Revenue
The following table provides a summary of revenue recognized:
Three Months Ended March 31,Six Months Ended March 31,
2024202320242023
(in thousands)
GSK$— $30,000 $2,685 $29,323 
Horizon— — — 21,667 
Takeda— 116,156 866 132,468 
Janssen— 111 — 355 
Amgen— — — 25,000 
Total$— $146,267 $3,551 $208,813 
Schedule of Receivables and Contract Liabilities
The following table summarizes the balance of receivables and contract liabilities related to the Company’s collaboration and license agreements:
March 31, 2024September 30, 2023
(in thousands)
Receivables included in accounts receivable$— $— 
Contract liabilities included in deferred revenue$— $866